To include your compound in the COVID-19 Resource Center, submit it here.

Seattle Genetics, Merck combining Keytruda and SGN-LIV1A

Seattle Genetics Inc. (NASDAQ:SGEN) and Merck & Co. Inc. (NYSE:MRK) partnered to evaluate Seattle

Read the full 146 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE